Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Lung Neoplasms 20Ovarian Neoplasms 15Carcinoma, Non-Small-Cell Lung 15Fallopian Tube Neoplasms 13Colorectal Neoplasms 10Pancreatic Neoplasms 9Carcinoma, Hepatocellular 9Melanoma 8Triple Negative Breast Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Breast Neoplasms 6Urinary Bladder Neoplasms 5Prostatic Neoplasms 5Neoplasm Metastasis 5Mycosis Fungoides 5Lymphoma, T-Cell, Cutaneous 5Carcinoma, Renal Cell 5Neoplasms 4Uterine Cervical Neoplasms 3Sezary Syndrome 3Sarcoma 3Myelodysplastic Syndromes 3Multiple Myeloma 3Lymphoma, T-Cell 3Leukemia, Myeloid, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Glioblastoma 3Endometrial Neoplasms 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3

Interventions

pembrolizumab 4Nivolumab 3toripalimab 2sintilimab 2Neoadjuvant Therapy 2Celecoxib 2tislelizumab 1spartalizumab 1relatlimab 1regorafenib 1fludarabine phosphate 1fludarabine 1durvalumab 1denileukin diftitox 1danvatirsen 1camrelizumab 1avelumab 1atezolizumab 1XELOX 1Taxes 1Surgical Procedures, Operative 1Radiation Dose Hypofractionation 1Paclitaxel 1Megestrol Acetate 1Medroxyprogesterone Acetate 1Ipilimumab 1Induction Chemotherapy 1Immunotherapy 1Immunoglobulin G 1Immune Checkpoint Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Turcot syndrome × Immunoglobulin G × Clear all
NCT02983578 2025-05-06

Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
39 enrolled
GastrointestinalThoracic

Turcot syndrome, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡